Back to Agenda
Newly Released Benefit-Risk Balance for Medicinal Products: A CIOMS Working Group XII Report
Session Chair(s)
Claudia Ana Ianos, MD
Senior Director, Safety Risk Management Lead, Pfizer, United States
The session reports the CIOMS WG XII Benefit-Risk Balance for Medicinal Products that formulates key principles for lifecycle benefit-risk assessments to inform decision-making and further the development of medicines that patients need.
Learning Objective : Discuss the Benefit-Risk Balance for Medicinal Products issued by CIOMS WG XII; Explain the conduct of high quality, balanced and comprehensive lifecycle benefit-risk assessments using the structured benefit-risk framework; Identify strategic guidance patient-centric benefit-risk assessment methodologies to improve transparency and understanding amongst key stakeholders.
Speaker(s)
Claudia Ana Ianos, MD
Senior Director, Safety Risk Management Lead, Pfizer, United States
Newly Released Benefit-Risk Balance for Medicinal Products: A CIOMS Working Group XII Report
Carmit Strauss, PHARMD
Executive Director, Head of Risk Management, Organ Toxicity and Benefit Risk , Takeda, United States
Newly Released Benefit-Risk Balance for Medicinal Products: A CIOMS Working Group XII Report
Scott Evans, PHD, MS
Professor and Founding Chair, Department of Biostatistics and Bioinformatics, George Washington University Milken Institute of Public Health, United States
Newly Released Benefit-Risk Balance for Medicinal Products: A CIOMS Working Group XII Report
Have an account?